B-cell-depletion therapy in SLEwhat are the current prospects for its acceptance?

Nature Reviews Rheumatology

Volumn 5, Issue 12, 2009, Pages 711-716

  Favas, Catarina ^a   Isenberg, David A ^b  

^a HOSPITAL CURRY CABRAL   (Portugal)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BETAMETHASONE; CHIMERIC ANTIBODY; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYCLOSPORIN A; IMMUNOGLOBULIN; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RITUXIMAB; STEROID;

B CELL DEPLETION; CLINICAL FEATURE; CLINICAL PROTOCOL; CLINICAL TRIAL; DISEASE ACTIVITY; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; INJECTION SITE REACTION; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPHOCYTE DEPLETION; LYMPHOMA; NOTE; OUTCOME ASSESSMENT; PLASMAPHERESIS; PRIORITY JOURNAL; REMISSION; RETREATMENT; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT DURATION;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; B-LYMPHOCYTES; CLINICAL PROTOCOLS; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; TREATMENT FAILURE;

EID: 74949085445     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2009.218     Document Type: Note

References (30)

1. Rahman, A. & Isenberg, D. A. Systemic lupus erythematosus. N. Engl. J. Med. 358, 929-939 (2008).
2. Hostmann, A., Jacobi, A. M., Mei, H., Hiepe, F. & Dorner, T. Peripheral B cell abnormalities and disease activity in systemic lupus erythematosus. Lupus 17, 1064-1069 (2008).
3. Reff, M. E. et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83, 435-445 (1994).
4. Merrill, J. T. et al. Efficacy and safety of rituximab in patients with moderately to severely active systemic lupus erythematosus (SLE): results from the randomized, doubleblind phase II/III study EXPLORER (abstract 12). Presented at the American College of Rheumatology Annual Meeting, 2008 October, San Francisco, CA, USA.
5. Li, E. K. et al. Is combination rituximab with cyclophosphamide better than rituximab alone in the treatment of lupus nephritis? Rheumatology (Oxford) 48, 892-898 (2009).
6. Looney, R. J. et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum. 50, 2580-2589 (2004).
7. Vigna-Perez, M. et al. Clinical and immunological effects of rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study. Arthritis Res. Ther. 6, R83 (2006).
8. Gottenberg J.-E. et al. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann. Rheum. Dis. 64, 913-920 (2005).
9. Smith, K. G., Jones, R. B., Burns, S. M. & Jayne, D. R. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: remission, relapse and re-treatment. Arthritis Rheum. 54, 2970-2982 (2006).
10. Gunnarson, I. et al. Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis. Arthritis Rheum. 56, 1263-1272 (2007).
11. Sutter, J. A. et al. A longitudinal analysis of SLE patients treated with rituximab (anti-CD20): factors associated with B lymphocyte recovery. Clin. Immunol. 126, 282-290 (2008).
12. Albert, D. et al. Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythematosus. Ann. Rheum. Dis. 67, 1724-1731 (2008).
13. Tokunaga, M. et al. Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann. Rheum. Dis. 66, 470-475 (2007).
14. Sfikakis, P. P. et al. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell co-stimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum. 52, 501-513 (2005).
15. Reynolds, J. A. et al. Effects of rituximab on resistant SLE disease including lung involvement. Lupus 18, 67-73 (2009).
16. Leandro, M. J., Cambridge, G., Edwards, J. C., Ehrenstein, M. R. & Isenberg, D. A. B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology (Oxford) 44, 1542-1545 (2005).
17. Cambridge, G. et al. B-cell depletion therapy in systemic lupus erythematosus: effect on autoantibody and antimicrobial antibody profiles. Arthritis Rheum. 54, 3612-3622 (2006).
18. Ng, K. P. et al. B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of response. Ann. Rheum. Dis. 66, 1259-1262 (2007).
19. Jonsdottir, T. et al. Treatment of refractory SLE with rituximab plus cyclophosphamide: clinical effects, serological changes, and predictors of response. Ann. Rheum. Dis. 67, 330-334 (2008).
20. Iannou, Y. et al. B cell depletion therapy for patients with systemic lupus erythematosus results in a significant drop in anticardiolipin antibody titers. Ann. Rheum. Dis. 67, 425-426 (2008).
21. Leandro, M. J., Cambridge, G., Edwards, J. C., Ehrenstein, M. R. & Isenberg, D. A. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum. 46, 2673-2677 (2002).
22. Tamimoto, Y. et al. A dose-escalation study of rituximab for treatment of systemic lupus erythematosus and Evans' syndrome: immunological analysis of B cells, T cells and cytokines. Rheumatology (Oxford) 47, 821-827 (2008).
23. Ng, K. P. et al. Repeated B-cell depletion in treatment of refractory systemic lupus erythematosus. Ann. Rheum. Dis. 65, 942-945 (2006).
24. Tanaka, Y. et al. A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus. Mod. Rheumatol. 17, 191-197 (2007).
25. Cambridge, G. et al. B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response. Ann. Rheum. Dis. 67, 1011-1016 (2008).
26. Lu, T. Y., Jonsdottir, T., Van Vollenhoven, R. F. & Isenberg, D. A. Prolonged B cell depletion following rituximab therapy in systemic lupus erythematosus. Ann. Rheum. Dis. 67, 1493-1494 (2008).
27. Anolik, J. H. et al. The relationship of FcγRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum. 48, 455-459 (2003).
28. Sanz, I. The conundrum of B cell depletion in SLE. Nat. Rev. Rheumatol. 5, 304-305 (2009).
29. vallerskog, T. et al. Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE. Clin. Immunol. 122, 62-74 (2007).
30. Calabrese, L. H., Molloy, E. S., Huang, D. & Ransohoff, R. M. Progressive multifocal leukencephalopathy in rheumatic diseases. Arthritis Rheum. 56, 2116-2128 (2007).